[HTML] mdpi.com

[HTML][HTML] Resistance of SARS-CoV-2 Omicron BA. 1 and BA. 2 variants to vaccine-elicited sera and therapeutic monoclonal antibodies

H Zhou, BM Dcosta, NR Landau, T Tada - Viruses, 2022 - mdpi.com
The recent emergence of the Omicron BA. 1 and BA. 2 variants with heavily mutated spike
proteins has posed a challenge to the effectiveness of current vaccines and to monoclonal …
被引用次数：50 相关文章

Resistance of SARS-CoV-2 omicron BA. 1 and BA. 2 variants to vaccine-elicited sera and therapeutic monoclonal antibodies.

H Zhou, BM Dcosta, NR Landau, T Tada - 2022 - cabidigitallibrary.org
The recent emergence of the Omicron BA. 1 and BA. 2 variants with heavily mutated spike
proteins has posed a challenge to the effectiveness of current vaccines and to monoclonal …

Resistance of SARS-CoV-2 Omicron BA. 1 and BA. 2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies

H Zhou, BM Dcosta, NR Landau, T Tada - Viruses, 2022 - search.proquest.com
The recent emergence of the Omicron BA. 1 and BA. 2 variants with heavily mutated spike
proteins has posed a challenge to the effectiveness of current vaccines and to monoclonal …

Resistance of SARS-CoV-2 Omicron BA. 1 and BA. 2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies.

H Zhou, BM Dcosta, NR Landau, T Tada - Viruses, 2022 - europepmc.org
The recent emergence of the Omicron BA. 1 and BA. 2 variants with heavily mutated spike
proteins has posed a challenge to the effectiveness of current vaccines and to monoclonal …
[HTML] nih.gov

[HTML][HTML] Resistance of SARS-CoV-2 Omicron BA. 1 and BA. 2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies

H Zhou, BM Dcosta, NR Landau, T Tada - Viruses, 2022 - ncbi.nlm.nih.gov
The recent emergence of the Omicron BA. 1 and BA. 2 variants with heavily mutated spike
proteins has posed a challenge to the effectiveness of current vaccines and to monoclonal …

Resistance of SARS-CoV-2 Omicron BA. 1 and BA. 2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies

H Zhou, BM Dcosta, NR Landau, T Tada - Viruses, 2022 - pubmed.ncbi.nlm.nih.gov
The recent emergence of the Omicron BA. 1 and BA. 2 variants with heavily mutated spike
proteins has posed a challenge to the effectiveness of current vaccines and to monoclonal …

Resistance of SARS-CoV-2 Omicron BA. 1 and BA. 2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies

H Zhou, BM Dcosta, NR Landau, T Tada - Viruses, 2022 - cir.nii.ac.jp
抄録< jats: p> The recent emergence of the Omicron BA. 1 and BA. 2 variants with heavily
mutated spike proteins has posed a challenge to the effectiveness of current vaccines and to …

Resistance of SARS-CoV-2 Omicron BA. 1 and BA. 2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies

H Zhou, BM Dcosta, NR Landau, T Tada - 2022 - agris.fao.org
The recent emergence of the Omicron BA. 1 and BA. 2 variants with heavily mutated spike
proteins has posed a challenge to the effectiveness of current vaccines and to monoclonal …

Resistance of SARS-CoV-2 Omicron BA. 1 and BA. 2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies.

H Zhou, BM Dcosta, NR Landau… - Viruses (1999-4915 …, 2022 - search.ebscohost.com
The recent emergence of the Omicron BA. 1 and BA. 2 variants with heavily mutated spike
proteins has posed a challenge to the effectiveness of current vaccines and to monoclonal …
[PDF] researchgate.net

[PDF][PDF] Resistance of SARS-CoV-2 Omicron BA. 1 and BA. 2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies. Viruses 2022, 14, 1334

H Zhou, BM Dcosta, NR Landau, T Tada - 2022 - researchgate.net
The recent emergence of the Omicron BA. 1 and BA. 2 variants with heavily mutated spike
proteins has posed a challenge to the effectiveness of current vaccines and to monoclonal …